203 related articles for article (PubMed ID: 19397855)
1. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide.
Edwards WB; Akers WJ; Ye Y; Cheney PP; Bloch S; Xu B; Laforest R; Achilefu S
Mol Imaging; 2009; 8(2):101-10. PubMed ID: 19397855
[TBL] [Abstract][Full Text] [Related]
2. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
Cai W; Chen K; Li ZB; Gambhir SS; Chen X
J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
[TBL] [Abstract][Full Text] [Related]
3. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
4. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
5. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis.
Cao J; Wan S; Tian J; Li S; Deng D; Qian Z; Gu Y
Contrast Media Mol Imaging; 2012; 7(4):390-402. PubMed ID: 22649045
[TBL] [Abstract][Full Text] [Related]
6. Radiosynthesis, Biological Evaluation, and Preclinical Study of a
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Pakdin-Parizi Z; Geramifar P
Contrast Media Mol Imaging; 2020; 2020():8421657. PubMed ID: 32292304
[TBL] [Abstract][Full Text] [Related]
7. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
8. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model.
Hsu AR; Hou LC; Veeravagu A; Greve JM; Vogel H; Tse V; Chen X
Mol Imaging Biol; 2006; 8(6):315-23. PubMed ID: 17053862
[TBL] [Abstract][Full Text] [Related]
9. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.
Ye Y; Bloch S; Xu B; Achilefu S
J Med Chem; 2006 Apr; 49(7):2268-75. PubMed ID: 16570923
[TBL] [Abstract][Full Text] [Related]
11. RGD-human serum albumin conjugates as efficient tumor targeting probes.
Chen K; Xie J; Chen X
Mol Imaging; 2009; 8(2):65-73. PubMed ID: 19397852
[TBL] [Abstract][Full Text] [Related]
12. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.
Liu Z; Jia B; Zhao H; Chen X; Wang F
Mol Imaging Biol; 2011 Feb; 13(1):112-20. PubMed ID: 20383594
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.
Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z
J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048
[TBL] [Abstract][Full Text] [Related]
15. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice.
Ferl GZ; Dumont RA; Hildebrandt IJ; Armijo A; Haubner R; Reischl G; Su H; Weber WA; Huang SC
J Nucl Med; 2009 Feb; 50(2):250-8. PubMed ID: 19164244
[TBL] [Abstract][Full Text] [Related]
16. Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
Ji S; Zheng Y; Shao G; Zhou Y; Liu S
Theranostics; 2013; 3(11):816-30. PubMed ID: 24312152
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
[TBL] [Abstract][Full Text] [Related]
18. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
19. Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
Briat A; Wenk CH; Ahmadi M; Claron M; Boturyn D; Josserand V; Dumy P; Fagret D; Coll JL; Ghezzi C; Sancey L; Vuillez JP
Cancer Sci; 2012 Jun; 103(6):1105-10. PubMed ID: 22448775
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
